A High-Resolution Map of Human Enhancer RNA Loci Characterizes Super-enhancer Activities in Cancer

Graphical Abstract

Highlights
- Super-enhancers contain discrete eRNA loci featured by sharp eRNA peaks
- Expression of such eRNA loci is regulated by dynamic, well-positioned nucleosomes
- eRNA signals confer explanatory power on quantitative traits beyond gene expression
- Super-enhancer activities are dysregulated in cancer by diverse mechanisms

Authors
Han Chen, Han Liang

Correspondence
hliang1@mdanderson.org

In Brief
Chen and Liang provide a high-resolution map of eRNA loci through which super-enhancer activities can be conveniently quantified by RNA-seq. The eRNA signals in cancer samples are clinically relevant and provide additional explanatory power for cancer phenotypes beyond those provided by mRNAs through resolving intra-tumor heterogeneity with enhancer cell-type specificity.
A High-Resolution Map of Human Enhancer RNA Loci Characterizes Super-enhancer Activities in Cancer

Han Chen and Han Liang
1Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
3Lead Contact
4Correspondence: hliang1@mdanderson.org
https://doi.org/10.1016/j.ccell.2020.08.020

SUMMARY

Although enhancers play critical roles in cancer, quantifying enhancer activities in clinical samples remains challenging, especially for super-enhancers. Enhancer activities can be inferred from enhancer RNA (eRNA) signals, which requires enhancer transcription loci definition. Only a small proportion of human eRNA loci has been precisely identified, limiting investigations of enhancer-mediated oncogenic mechanisms. Here, we characterize super-enhancer regions using aggregated RNA sequencing (RNA-seq) data from large cohorts. Super-enhancers usually contain discrete loci featuring sharp eRNA expression peaks. We identify >300,000 eRNA loci in ~377 Mb super-enhancer regions that are regulated by evolutionarily conserved, well-positioned nucleosomes and are frequently dysregulated in cancer. The eRNAs provide explanatory power for cancer phenotypes beyond that provided by mRNA expression through resolving intratumoral heterogeneity with enhancer cell-type specificity. Our study provides a high-resolution map of eRNA loci through which super-enhancer activities can be quantified by RNA-seq and a user-friendly data portal, enabling a broad range of biomedical investigations.

INTRODUCTION

Enhancers are key non-coding DNA sequences regulating their target genes (Pennacchio et al., 2013). It has been an evolving concept since the early identification of the Simian virus 40 (SV40) DNA sequence enhancing local gene expression in the 1980s (Banerji et al., 1981), followed by the discovery of endogenous locus control regions (Levings and Bungert, 2002). The chromatin modification of H3K4me1 and H3K27ac are known to be effective markers for enhancer identification (Creyghton et al., 2010; Heintzman et al., 2007), and later more epigenetic markers, such as H3.3 and H2A.Z, were reported to be associated with enhancer functions (Goldberg et al., 2010; Jin et al., 2009; Lawrence et al., 2016). With many more enhancer elements characterized in the human genome (ENCODE Consortium, 2012), the concepts of “stretch-enhancer” and “super-enhancer” were then proposed to refer to large genomic domains with enriched enhancer activity (Pott and Lieb, 2015). Using a combination of high-throughput assays, the ENCODE project has identified the genome-wide DNA regions with enhancer-like features in >100 cell types (ENCODE Consortium, 2012). On activation, enhancers open the local chromatin and expose the DNA motifs to attract TFs that can further recruit RNA polymerases (usually RNA Pol II) to generate enhancer RNAs (eRNAs) (Heinz et al., 2015; Murakawa et al., 2016). First identified in neuronal tissues (De Santa et al., 2010; Kim et al., 2010), expressed enhancers were systematically annotated (~65,000 ones) by the FANTOM project in ~400 human tissues and cell types using the cap analysis of gene expression (CAGE-seq) technique targeting the molecules with 5’ cap (Andersson et al., 2014). While some studies show strong evidence that eRNAs are functional in gene regulation by some master TFs and repressors, such as p53, estrogen receptors, and Rev-Erbs (Lam et al., 2013; Li et al., 2013; Melo et al., 2013), what proportion of the eRNAs are functional or merely the by-products of enhancer activation (Catarino and Stark, 2018; Kim et al., 2015) remains an open question.

The critical roles of enhancers in cancer development and tumor therapeutic response have been increasingly recognized (Bahr et al., 2018; Mack et al., 2018; Takeda et al., 2018). But quantifying enhancer activities in clinical tumor samples remains challenging in practice. RNA sequencing (RNA-seq) data are a convenient, rich information resource for eRNA quantification.
and enhancer activity approximation (Buenrostro et al., 2013; Chen et al., 2018a; Murakawa et al., 2016). In particular, it works well based on the CAGE-defined enhancers because of their precise eRNA location annotation (Chen et al., 2018a, 2018b; De Santa et al., 2010). Based on CAGE-defined enhancers annotated by FANTOM, using RNA-seq data from The Cancer Genome Atlas (TCGA), we recently demonstrated the utility of the eRNA signals in predicting patient survival and regulation of therapeutic targets (Chen et al., 2018a). However, the CAGE-defined enhancer annotation only covers a small fraction of eRNA loci (~15,000) (Andersson et al., 2014; ENCODE Consortium, 2012). Moreover, unlike RNA-seq, CAGE-seq cannot be easily applied to large cohorts of tumor samples, such as TCGA, thereby limiting the power of connecting eRNAs with clinical phenotypes. Therefore, it is highly valuable to systematically identify the precise eRNA loci that can be measured by routine RNA-seq data. To depict a more comprehensive set of eRNA loci beyond those already annotated by FANTOM, we focused on the super-enhancer regions defined by Hnisz et al. (2013). Although the concept of super-enhancers is still open to discussion (Pott and Lieb, 2015), we investigated them for the following scientific and technical reasons. First, these super-enhancer regions cover >370 Mb DNA sequence in length and represent regions with the most enriched regulatory signals in the human genome. Dysregulation of super-enhancers is frequently associated with various developmental diseases, including cancer (Alam et al., 2020; Hnisz et al., 2013; Loven et al., 2013; Whyte et al., 2013), indicating their potential biomedical significance (Shin, 2015). Second, compared with typical enhancers, super-enhancers show much stronger signals of RNA Pol II binding (Hnisz et al., 2013), implying that their eRNAs may be more actively transcribed and could potentially be detected by TCGA mRNA-seq data even without CAGE-seq-based annotation (Chen et al., 2018a). Third, compared with typical enhancers (~200 bp), super-enhancers are much longer (usually >10 kb) (Pott and Lieb, 2015). Thus, background transcription noise across the super-enhancer bodies substantially confounds the real enhancer activation signals (Berretta and Monllon, 2009; Nagalakshmi et al., 2008; Thompson and Parker, 2007), necessitating the precise separation of the eRNAs from nearby genomic regions (Pott and Lieb, 2015). Finally, unlike other super-enhancers proposed later, these super-enhancer regions have been systematically annotated in a variety of tissues and cell types (86 in total) using consistent H3K27ac ChIP-seq profiles (Hnisz et al., 2013), thereby providing a reliable recurrent frequency of super-enhancer activation across tissues. We hypothesize that the precise eRNA loci within super-enhancers can be resolved by analyzing aggregated RNA-seq profiles that combine the RNA-seq data of many individual samples. This is because eRNA reads associated with real enhancer activity recurrently accumulate, whereas background transcription noise tends to occur stochastically. The large number of RNA-seq reads obtained would compensate for the statistical power compromised by the low eRNA expression level typically observed in a single sample. Furthermore, the large sample size would help distinguish differential activation of neighbor eRNA loci within a super-enhancer. With the precise eRNA loci thus defined, it would then be possible to quantify the sample-specific eRNA levels using routine RNA-seq data, thereby enabling a broad range of biomedical investigations of super-enhancer activities, especially in clinical samples.

RESULTS

Recurrent eRNA Expression Peaks in Super-enhancers

Figure 1 shows an overview of our study. Since super-enhancers are largely tissue-specific and collectively constitute up to ~377 Mb of mappable non-coding DNA sequences (Table S1) (Hnisz et al., 2013), we first focused on a subset of 1,531 (out of ~58,000) core super-enhancers (~5 Mb) that were consistently identified and activated in >20 (out of 86) tissue/cell types (Hnisz et al., 2013) (Table S2) for exploratory analysis. To confirm their RNA Pol II binding activities, we examined the association of their eRNAs with H3K27ac in 140 cell lines and observed a positive correlation in the vast majority (>80%) of these core super-enhancers (Figure S1A–E). Using TCGA RNA-seq data (>10,000 samples of 32 cancer types), we generated the aggregated RNA-seq profile for each cancer type to elucidate the eRNA transcriptional landscape in super-enhancers, integrated them with the nucleosome profiling data of 29 tissue/cell types, validated the patterns using GTEx RNA-seq data (~10,000 samples of 31 normal tissues) and FANTOM CAGE-seq enhancer data (>250 human cell lines), and inferred the underlying principles for identifying precise eRNA loci. Second, we applied the rules derived from this core set to the whole super-enhancer set (~377 Mb) to construct a fine map of ~300,000 eRNA loci. Third, through a case study of tumor response to immunotherapy, we demonstrated the power of such a map for eRNA analysis in explaining complex genotype-phenotype relationships. Finally, we performed a pan-cancer analysis of these eRNA loci by integrating other TCGA molecular data and built a user-friendly data portal, The Cancer eRNA Atlas, for the scientific community to use all the resources generated in this study.

To learn the rules for pinpointing eRNA loci, we calculated the eRNA expression levels for all tandem 10 bp windows of DNA in the 5 Mb core super-enhancer set using an aggregated RNA-seq dataset for each of the 32 cancer types (>10,000 TCGA samples in total). Looking at the transcriptional landscape of super-enhancers, we noticed highly recurrent sharp eRNA expression peaks across super-enhancer bodies, as illustrated by a ~670 bp region in Figure 2A. This is one of the super-enhancer regions most consistently identified in nearly half (39 out of 86) of the tissue/cell types (Figure S2A), and also one of the most widely expressed regions across cancer types (Figures 2A, 2B, S2B, and S2C). In 28 of the 32 cancer types, we observed five sharp eRNA expression peaks with lengths of only a few dozen base pairs near the 70th, 210th, 390th, 520th, and 640th nucleotide positions. Interestingly, not only the location of the eRNA peaks but also their relative heights (expression levels) showed recurrent patterns, leading to four distinct clusters of the 32 cancer types (Figure 2B). Such an eRNA pattern was further confirmed by the independent GTEx dataset of 31 normal tissues (Figures 2C, S2D, and S2E) (GTEx Consortium, 2017).

To systematically identify such eRNA peaks, we searched the 1,531 core super-enhancers for local maximums of expression levels in all possible 200 bp windows and identified a total of 29,828 eRNA expression peaks recurrent in at least three
TCGA cancer types (false discovery rate [FDR] = 0.12, permutation analysis; FDR <0.01 when recurrent in more than three cancer types, Figure S3A). Interestingly, an overwhelming proportion of these eRNA peaks showed a length of only 100 bp, which then quickly decreased to the baseline (Figure 3A). This pattern of a short pulse held true when the maximum search range was extended to 400 or 600 bp (Figures S3B and S3C), or using the GTEx dataset (Figures 3B, S3D, and S3E). A typical peak (the median of 29,828 peaks) has a maximum expression level that quickly drops by 2.3-fold as close as 50 bp on either side (Figure 3C). Furthermore, we detected no enrichment of splicing motifs on the body or boundaries of these peaks, in contrast to the strong signals observed on intron-exon junctions (Figures S3F and S3G). We observed a strong signal of tandem TF binding motifs on either boundary of the eRNA peaks on both strands (Figure 3D), supporting that they resulted from transcriptional initiation rather than RNA splicing, similar to that of the FANTOM eRNA loci with precise transcription start sites (TSSs) (5’ cap). These results suggest that there are biologically meaningful eRNA loci in super-enhancers, and they generate discrete, recurrent, short eRNAs that can be readily detected by RNA-seq.

**eRNA Expression Is Regulated by Well-Positioned Nucleosomes**

The eRNA peaks we observed were as short as ~100 bp (Figures 2A and 3C), and this length is close to a 147 bp DNA unit occupied by a typical nucleosome, the unit of chromatin organization. Because the nucleosome dynamics is a critical feature of TF binding on DNA motifs (He et al., 2010; West et al., 2014), we hypothesized that the eRNA peaks in super-enhancers are shaped by changes in chromatin organization at the nucleosome level in response to the super-enhancer activation by TF binding. When the super-enhancer is silent, binding motifs are protected from being accessed by TFs through promiscuous interactions. Upon activation, the nucleosome is disassembled, making the motifs available for TF recognition, which would then initiate transcription and generate the observed eRNAs. After activation, the enhancer sequence released from the TFs would soon be re-claimed by the nucleosome for protection (Jin et al., 2009; Mueller et al., 2017). The “state switch” of these nucleosomes is likely to release one unit of 147 bp DNA, thereby explaining the short (~100 bp) and sharp shape of the eRNA peaks (Figure 3A). Notably, even though the core super-enhancers we studied are likely to have effects in multiple tissues, they are still tissue-specific and should, therefore, be silent in the majority of the tissues (they are expected to be active in >20% of the tissue types only). As a result, nucleosomes should occupy the eRNA loci in most tissues surveyed, thereby allowing the detection of well-positioned nucleosomes when examining nucleosome binding signals across tissues. When the super-enhancer is activated, the situation can be more complicated. Upon transcription initiation, the nucleosome occupying an eRNA locus would have to be replaced by a TF (Brahma and Henikoff, 2019; He et al., 2010). However, the TF on this “open” DNA competes with intruding nucleosomes that often contain the histone variants H3.3 and H2A.Z (Jin et al., 2009; Mimy, 2010; Wasson and Hartemink, 2009) in a tissue-specific manner (Goldberg et al., 2010). The nucleosome turnover at this site leads to its observation as a...
Figure 2. Recurrent eRNA Expression Peaks in Super-enhancers

(A) The eRNA expression on chr3:50,265,725-50,266,396 in 4 cancer types representing the 4 clusters (C1-C4) of the 32 TCGA cancer types. Each bar represents a 10 bp window in the 672 bp region. The y axis shows the reads per kilobase of transcript, per million mapped reads (RPKM) in the 10 bp windows, and the x axis represents the relative genomic coordinates (bp) in the region. The loci on the 70th, 210th, 390th, 520th, and 640th bp have local maximum RPKMs. These and their flanking 20 bp regions are highlighted.

(B) A heatmap showing unsupervised clustering of the 32 cancer types based on the relative eRNA expression of all 10 bp windows in this 672 bp region. The eRNA expression levels (RPKM) are normalized into Z scores within the columns of the heatmap.

(C) The number of TCGA cancer types (top) or GTEx tissue types (bottom) with local maximum RPKM values of sliding 200 bp windows in this region. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD/READ, colon/rectum adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic cancer...
fragile nucleosome (Brahma and Henikoff, 2019), depending on a variety of factors, such as MNase digestion time (Brahma and Henikoff, 2019), replication stage (Ramachandran and Henikoff, 2016), and salt concentration (Jin et al., 2009). Recent studies have shown that the widespread nucleosome turnover in the actively transcribed gene bodies or enhancers is generally rapid enough so that no change of nucleosome occupation signal could be observed (Brahma and Henikoff, 2019; Mueller et al., 2017).

To test this hypothesis, we collected the MNase-seq data of 29 tissue/cell types (Figure 5A) and aligned the nucleosome signals flanking the 29,828 peaks. We indeed observed well-positioned nucleosomes on the eRNA expression peaks in all 29 human tissues (Figures 4A and S4B), and even in sperms where nucleosomes are highly sparse (Figure 4B) (Hammoud et al., 2009). The occupancy of these nucleosomes is conserved across macro-evolution, with similar occupancy observed in five tissues from pig, mouse, and human (Figure 4A, middle and bottom panel) with available MNase-seq data (Jiang et al., 2018), indicating the functional importance of nucleosome occupancy at these positions. Thus, our analysis reveals the epigenetic regulation mediated by nucleosome binding on the transcriptional initiation of eRNAs in super-enhancers (summarized in Figure 4C), similar to that observed for gene TSSs.

Global Identification of eRNA Loci in Super-enhancers

From the above analysis, we made two key observations related to the eRNA loci in super-enhancers: (1) a super-enhancer usually contains multiple eRNA loci generating short eRNA species <100 bp; and (2) these eRNA loci tend to coincide with well-positioned nucleosomes. We, therefore, generalized our analysis to the whole set of super-enhancers (~377 Mb), which would otherwise suffer greatly from the noise of global transcription background without precise enhancer locus annotation.

We first identified the loci with local maximum RPKM for all possible 140 bp windows in the super-enhancers in each TCGA cancer type, generating a total of ~4 million eRNA peak positions. We then calculated the nucleosome signals on the flanking 140 bp for each peak position in 27 MNase-seq datasets (the two sperm samples were excluded). To characterize the major patterns of nucleosome binding, we performed principal-component analysis on these signals (Figure 5A and S5A–S5C). The first three principal components (PCs) collectively explained ~85% of the total variations. PC1 effectively reflected the averaged local MNase-seq signal intensity on the flanking 140 bp regions (Figure 5A; Pearson’s R = 0.96; p < 2 × 10−16). PC2 and PC3 were independent of PC1 and from each other (Figures S5E–S5G). They represented the phase of nucleosome positioning near the eRNA peak. Specifically, PC2 and PC3 divided the 4 million peaks into three groups (shown in different colors in Figure 5A): PC2 represented the relative occupancy of nucleosome up- or downstream of the peak position (Figures 5B and S5C) while a negative PC3 indicated a synchronization between nucleosome occupancy and eRNA expression signal (Figures 5D, SSH, and S5J). Thus, a negative PC3 value was a good indicator of an eRNA expression peak aligned with a well-positioned nucleosome, the eRNA locus of our interest. Strikingly, a negative PC3 exhibited a strong correlation with the probability of a common SNP in the eRNA peaks being a GTEx eQTL (R = −0.93; p = 5.2 × 10−6; Figure 5E), indicating the functional significance of the eRNA peaks coinciding with well-positioned nucleosomes. In contrast, PC1 was a much worse indicator than PC3, emphasizing the importance of nucleosome positioning rather than the affinity of the local sequence to nucleosomes (R = −0.39; p = 0.03; Figure 5F). As true eRNA signals, rather than transcriptional noise, should be synchronized across multiple tissues where they function, we found that PC3 was strongly associated with either the probability of the region being identified as a super-enhancer in the original 86 tissue/cell types (R = −0.89; p = 3.7 × 10−16; Figure 5G) or the recurrent frequency identified in the 32 TCGA cancer types (R = −0.90; p = 6.7 × 10−16; Figure 5H).

As described above, the eRNA expression peak also tends to form sharp and short transcription pulses ~100 bp in length, which can be measured as the relative peak height, by comparing the peak expression with those of the two “gulfs” ~50 bp away from the peak (Figure 5C). We found this value to be strongly correlated with the probability of a common SNP in the eRNA peaks being a GTEx eQTL signal (R = −0.996; p < 2 × 10−12; Figure 5I) or the probability of the peak region being a super-enhancer in the 86 tissue/cell types (R = 0.86; p = 8.9 × 10−13; Figure 5J). Therefore, we decided to integrate the eRNA peaks with well-positioned nucleosomes to identify eRNA loci systematically.

Based on a permutation analysis of eRNA loci, we developed two criteria to identify candidate eRNA loci by searching the 4 million eRNA peaks for those (1) coincident with well-positioned nucleosomes (PC3 <0) and (2) with sharp eRNA expression peaks (relative peak height >0.05). We identified >300,000 such eRNA loci (FDR <0.1, permutation analysis) in the ~377 Mb super-enhancer regions (Table S3). This procedure strongly enriched recurrent loci (Figures S5J–S5K, ranging from ~50,000 to ~120,000 loci per cancer type) that retained high tissue specificity compared with protein-coding genes (Figure S5L). This procedure also identified many more such loci in the super-enhancers than in other regulatory regions or non-regulatory sequences (Figure S5M), consistent with the enrichment of RNA Pol II ChIP-seq signals in the super-enhancers. As visualized on chromosome 22, dense eRNA loci were observed across the super-enhancer regions (Figure 5K, top and middle panels). Interestingly, both heterogeneous and highly co-activating modules were frequently found in genomic neighborhoods. For example, the blue super-enhancer region formed two distinct clusters, whereas a highly complex co-activation pattern was observed across the structure of the green super-enhancer (Figure 5K, bottom panel).

We then evaluated the quality of these eRNA loci in several aspects. First, to confirm if the identified eRNA loci represent the true transcription initiation, rather than transcriptional noise, we analyzed the average enhancer CAGE-seq signal around the

See also Figure S2.
eRNA loci (Andersson et al., 2014). Indeed, there was a sharp peak of enhancer transcription initiation signal detected by CAGE-seq at \( \pm 60 \) bp upstream of the eRNA loci on either the Watson or Crick strand (Figures S6A and S6B). The \( \pm 120 \) bp distance between the two CAGE-seq peaks flanking the eRNA loci is consistent with the role of well-positioned nucleosomes we proposed (Figure 4C). Although the read depth of CAGE-seq data was much lower than that of the RNA-seq data, the flanking CAGE-seq peaks showed an enrichment relative to the genomic background (Figures S6C and S6D). Despite the local enrichment of CAGE-seq signals near our eRNA loci (Figures S6A and S6B), it should be emphasized that \( \approx 77\% \) of the \( \approx 300,000 \) eRNA loci are at least 2 kb away from any FANTOM-annotated enhancer (Figure S6E), highlighting the discovery power of our approach for novel eRNA loci. Second, we called well-positioned nucleosomes in 15 paired-end MNase-seq samples (Chen et al., 2013) and found \( >60\% \) of the eRNA loci to be occupied by well-positioned nucleosomes in \( \geq 5 \) samples studied (Figure S6F), indicating the robustness of this pattern. Taken together, using the key features identified in the core super-enhancers, we systematically identified candidate eRNA loci in the whole set of super-enhancers. These eRNA loci feature well-positioned nucleosomes (as in gene TSSs [Jiang and Pugh, 2009]) and are enriched in eQTL associations, suggesting that these eRNA loci are functionally important and represent quantifiable units for studying super-enhancer activities using routine RNA-seq data.

**eRNA Expression Provides Extra Quantitative Power for Clinical Phenotypes**

Because the effects of enhancers must ultimately converge on their target genes, one key question is whether and how the eRNA loci we detected can provide additional quantitative power...
in dissecting genotype-phenotype relationships (Chen et al., 2018c). With a comprehensive catalog of eRNA loci (>300,000), we hypothesize that eRNA signals better explain quantitative traits than gene expression because of the tissue or cell-type specificity of the super-enhancers, which can be illustrated as follows. In a hypothetical case, the cell-type-specific enhancers A, B, and C are regulators of the gene X in cell types A, B, and C, respectively (Figure 6A). However, only cell type A contributes to a quantitative trait through the activity of gene X. As a result, only the activation level of enhancer A should be strongly associated with the trait, while the predictive power of gene X is compromised by including the expression signals of gene X in cell types B and C (which have no effects on the phenotype of interest). This scenario is particularly relevant in the RNA-seq analysis of clinical tumor samples in two aspects. First, according to a recent CAGE-based study, a much larger proportion of eRNAs (>30%) is highly cell-type specific compared with mRNAs (<5%). Super-enhancers are even more cell-type specific, and their activation often represents cell lineages in H3K27ac ChIP-seq studies (Hnisz et al., 2013). Second, clinical tissue samples (e.g., solid tumors) usually are a mixture of various cell types (Marusyk et al., 2020). The eRNA peaks identified in this study are mostly restricted to a few cancer types (Figure S5K), distinct from the protein-coding genes in the same dataset (Figure S5L), which are readily detectable in many tissues. Therefore, the expression level of protein-coding genes from bulk RNA-seq data largely reflects the average signals...
Figure 5. Identification of eRNA Loci in the Genome-Wide Super-enhancer Regions

(A) Principal-component analysis (PCA) of nucleosome positioning on the flanking 140 bp sequences around ~4 million loci of local maximum eRNA RPKMs. The color represents the distance between the position with the maximum MNase-seq signal and the position of the local maximum eRNA RPKMs. Only the first 10,000 loci are plotted for convenient visualization.

(B–D) The sliding mean of mapped MNase-seq reads in all 27 nucleosome profiles in the flanking 140 bp DNA (each side) were plotted for loci meeting the indicated criterion: PC2<0/PC3>0 (B), PC2>0/PC3<0 (C), or PC2>0 (D). The sequences meeting the indicated criterion were aligned with the loci of the local maximum eRNA RPKMs at the center (0 bp). Each point represents a 10 bp window. The mean number of mapped MNase-seq reads was calculated for all 10 bp windows with the same relative positions to the peaks (indicated by the x axis).

(E and F) The correlation of the PC3 (E) or PC1 (F) quantile with the relative probability for a common SNP in its flanking 20 bp region to be identified as a GTEx eQTL. For loci with indicated PC3/PC1 quantile, this probability was calculated by dividing the number of GTEx eQTLs in the region with the total number of common SNPs (minor allele frequency >20% in the 1000 Genome Project) in the region. The resulting probabilities were normalized by dividing them with the minimum value of all quantiles (y axis). Each error bar represents one standard error of the indicated probability estimated using the binomial distribution. p Values indicate the significance of the Pearson’s correlation coefficients (PCCs).

(legend continued on next page)
eRNA Loci Are Dysregulated and Show Clinical Relevance in Cancer

To study super-enhancer dysregulation in human cancers, we first compared the expression levels of the ~300,000 eRNA loci between tumors and normal samples in 12 cancer types with ≥20 tumor-normal sample pairs and observed a global activation of super-enhancers in many cancers (Figure 7A), similar to that of typical enhancers we recently reported (Chen et al., 2018a). Interestingly, a substantial portion of the eRNA loci was affected by the driver events of focal copy-number amplification, ~4-fold more likely than being affected by driver deletion events (Figure 7B). This pattern was in sharp contrast to the contributions of copy-number driver events affecting protein-coding genes, for which focal deletions were ~1.2-fold more likely to occur (Figure 7C). The same pattern held true when recurrent events across multiple cancer types were merged (Figure 7D).

CpG methylation plays a critical role in controlling its nearby regulatory elements (Skvortsova et al., 2019). We found ~4,000 eRNA loci containing at least one CpG methylation probe of the Human Methylation 450k array used in TCGA project. In these probes, 1,187 (~30%) CpG dinucleotides showed significant changes at the DNA methylation level (Figure 7E; >20% absolute changes; FDR < 0.01; paired t test). These changes can be clearly divided into two clusters (hypo- and hypermethylation) with near consistency across different cancer types (Figure 7E). These methylation changes were associated with the expression changes of the 360 eRNA loci (Figures 7F and 7G; log_{2} fold change >2; FDR <0.05; paired t test) in the same patients, of which 174 (~50%) events were the deactivation of eRNA loci with hypermethylated CpGs inside (Figure 7G). We observed another 93 activation events on eRNA loci containing hypomethylated CpGs (Figure 7F). These results support that the hypermethylation of within-peak CpGs is an important indicator of super-enhancer deactivation during tumorigenesis (Skvortsova et al., 2019). Finally, we found ~50,000 eRNA loci (or ~62,000 associations) whose expression levels were associated with clinical outcomes, such as patient survival time, in at least one cancer type (Figure 7H), supporting their functional and clinical relevance.

To facilitate the community use of our results, we have built a user-friendly data portal, The Cancer eRNA Atlas (https://bioinformatics.mdanderson.org/public-software/tcea). This data portal provides (1) the detailed annotation of mappable non-coding super-enhancer regions (~377 Mb) surveyed in this study; (2) the details of the core super-enhancer regions (~5 Mb); (3) the expression level (RPKM) of >300,000 super-enhancer transcription units in >10,000 TCGA tumor samples, >9,600 GTEx normal
Figure 6. The eRNA Loci in Super-enhancers Provide Additional Explanatory Power for Immunotherapeutic Response by Resolving Tumor Heterogeneity

(A) A cartoon model illustrating how cell-type-specific enhancers can increase the explanatory power of quantitative traits by resolving tumor heterogeneity. Left: a hypothetical bulk tumor consists of three different cell types in which enhancer A, B, or C controls the expression of gene X, respectively; and only cell type C contributes to a phenotype of interest. Right: distinct correlation patterns when correlating different eRNA or mRNA signals with the phenotype.

(B) The p value distribution of coding genes through the differential analysis in a cohort of 28 melanomas with different responses to anti-PD1 immunotherapy (q < 0.1).

(C) The p value distribution of eRNAs through the differential analysis in the same cohort as in (B) (q < 0.05; ANOVA test).

(D) Unsupervised clustering based on the RPKM values of the 164 eRNA loci across the 28 tumors. The RPKMs were normalized by each eRNA peak (row) in the 28 tumors.

(E) GSEA results of the 36 genes targeted by at least one GTEx eQTL in the 164 eRNA locus regions (defined as the flanking 50 bp DNA on either side of the eRNA loci). p Values and FDR were calculated by the GSEA webserver.

Please cite this article in press as: Chen and Liang, A High-Resolution Map of Human Enhancer RNA Loci Characterizes Super-enhancer Activities in Cancer, Cancer Cell (2020), https://doi.org/10.1016/j.ccell.2020.08.020
samples, and >900 CCLE cell lines; (4) the super-enhancer eRNA loci and genes associated with responses to immunotherapy; (5) the associations of super-enhancer transcription units with clinical outcome, somatic copy-number alteration, and CpG methylation in TCGA datasets; and (6) the 3D eRNA locus/promoter interactions in >50 ChIA-PET or HiC datasets (Wang et al., 2018), resulting in a strong enrichment of positive eRNA/target-gene co-expression (Figures S7E–S7H); (7) additional super-enhancer

(F) The combined expression level (sum of log2RPKM) of the 8 non-redundant genes in (E) exhibits prognostic power in a cohort of 42 patients receiving anti-CTLA-4 immunotherapy (p = 0.037; one-sided Fleming-Harrington test).

See also Figure S7 and Table S4.

Figure 7. Pan-cancer Analysis of the eRNA Loci in Super-enhancers

(A) Differential expression of eRNA loci between tumor and normal samples in 12 cancer types with >20 tumor-normal pairs; \(*p < 0.01\) (paired t test).

(B) Numbers of driver focal somatic copy-number alterations (SCNAs) affecting at least one eRNA locus but no protein-coding genes. Driver focal SCNAs were detected by GISTIC.

(C) The number of driver focal SCNAs affecting the protein-coding genes.

(D) The same analysis as in (B) except that the overlapping focal SCNAs identified in different cancer types were merged.

(E) Differential CpG methylations in eRNA loci between tumor and normal samples in 10 cancer types with methylation profiles of >10 tumor-normal pairs available. Hypo/hypermethylation in tumors, compared with normal, is indicated as red/blue. Only significant changes are colored (q < 0.01; paired t test). Probes with absolute changes >20% in at least one cancer type were included in the unsupervised clustering.

(F and G) The number of differential expressions for eRNA loci, including significant hypomethylation (F) or hypermethylation (G) changes as defined in (E) (>20% and q < 0.01). Differential expression changes were determined by paired t test.

(H) The number of eRNA loci with prognostic power on overall survival, progression-free interval, or disease-specific survival in 32 TCGA cancer types (q < 0.05; log rank test).
regions: we collected ~350 H3K27ac profiles from Cistrome (Liu et al., 2011) and SEdb (Jiang et al., 2019) and annotated the potential eRNA loci in an additional ~350 Mb putative super-enhancer.

**DISCUSSION**

We recently showed that cohort-based eRNA expression analysis is powerful in studying cancer mechanisms based on CAGE-seq-defined enhancers (Chen et al., 2018a, 2018b). However, it is difficult to apply a similar strategy to super-enhancers, mostly due to their large size (>10 kb in length). By integrating dynamic nucleosomes with eRNA expression signals from aggregated RNA-seq data, we developed a systematic strategy to identify their eRNA loci, wherein the tissue-specific property of super-enhancers is the key. In a tissue A where the super-enhancer is active, and a motif is required by the TFs, the local nucleosome is recognized and labeled by chromatin modifiers and then intentionally opens to allow the TF-DNA binding; whereas in the majority of tissues where the super-enhancer is silent, a well-positioned nucleosome is necessary to prevent the TF-motif contact and suppress unwanted enhancer activation (He et al., 2010; Zhang et al., 2008). This is why we could observe well-positioned nucleosomes coinciding with the sharp transcriptional peaks when integrating eRNA expression and nucleosome position data across different tissues. An alternative model is that, during rapid transcription initiation on enhancers, cells can alter DNA accessibility of well-positioned nucleosomes using ATP-powered chromatin remodelers without changing nucleosome occupation (Mueller et al., 2017). Both models suggest the importance of well-positioned nucleosomes on the TF-motifs in enhancers. Strikingly, the constraint on well-positioned nucleosomes is conserved across a billion years of evolution, indicating its essential role in maintaining the overall transcriptional structure of super-enhancers. In contrast to the eRNA loci we detected, background transcription is a nature of genome organization that can be caused by DNA breathing (Chen et al., 2012), replication (Brar et al., 2012), or repair (Michelini et al., 2017). As a result, the low background transcription would amount to substantial noise in large-size regulatory elements, such as super-enhancers. Importantly, this transcriptional noise does not have a protective (well-positioned) nucleosome accompanying it in other tissues, or when the DNA is closed (Figures 5E and 5I); thus, it is more likely to be associated with fuzzy nucleosomes (Mavrich et al., 2008).

One limitation of our study is that the public, consortium RNA-seq datasets (TCGA or GTEx) used are poly(A)+ selected, and can only capture a subset of eRNA signals. But the aggregated RNA-seq data across hundreds of individual samples help mitigate this limitation and still allow the detection of a large number of eRNA loci. With the eRNA loci thus defined, the most frequently generated poly(A)+-selected RNA-seq data can be readily used to characterize super-enhancer activities. We expect to detect more eRNA loci using a similar approach on rRNA-depleted RNA-seq data and will revisit this when a large amount of such RNA-seq data become available.

In summary, our study systematically identified >300,000 eRNA loci in ~377 Mb super-enhancer regions, allowing the possibility to quantify the activation of super-enhancers using RNA-seq data. As demonstrated in the case study of cancer immunotherapy, the eRNA levels can largely retain cell-type-specific signals, whereas the mRNA expression levels by bulk RNA-seq data are more likely to be confounded by different cell types within a tumor sample. Thus, the eRNA loci map defined here will increase the power to explain quantitative traits beyond gene expression, thereby opening a new horizon to investigate the biological functions and potential applications of super-enhancers in various developmental and disease processes.

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead Contact
  - Materials Availability
  - Data and Code Availability
- **METHOD DETAILS**
  - Annotation of Super-enhancers
  - Analysis of eRNA and ChIP-seq H3K27ac Signals
  - Super-enhancer eRNA Expression Profiles
  - Motif Discovery and Chromatin Organization in Super-enhancer eRNA Peaks
  - eRNA Expression Analysis for Tumor Response to Immunotherapy
  - Integrative Analysis of eRNA Loci with Other TCGA Molecular and Clinical Data
  - Analysis of eRNA-Locus/Gene Co-expression and 3D Chromatin Interactions

**SUPPLEMENTAL INFORMATION**

Supplemental Information can be found online at https://doi.org/10.1016/j.ccell.2020.08.020.

**ACKNOWLEDGMENTS**

This study was supported by grants from the U.S. NIH (U24CA209851, U01CA217842, and P50CA221703 to H.L., and P50CA016672), an MD Anderson Faculty Scholar Award (to H.L.), the Lorraine Dell Program in Bioinformatics for Personalization of Cancer Medicine (to H.L.), and a training fellowship from the Gulf Coast Consortia on the NLM Training Program in Biomedical Informatics and Data Science (T15 LM007093 to H.C.). We thank Kamalika Mojumdar, Mei-Ju May Chen, and Jun Li for assistance.

**AUTHOR CONTRIBUTIONS**

H.C. and H.L. conceived and designed the study, performed data analysis, and wrote the manuscript.

**DECLARATION OF INTERESTS**

H.L. is a shareholder and scientific advisor to Precision Scientific Ltd.

Received: July 9, 2019
Revised: July 21, 2020
Accepted: August 28, 2020
Published: October 1, 2020


within individual DNA molecules. Genome Res. 17, 284–292.


Cancer Cell

Article


Please cite this article in press as: Chen and Liang, A High-Resolution Map of Human Enhancer RNA Loci Characterizes Super-enhancer Activities in Cancer, Cancer Cell (2020), https://doi.org/10.1016/j.ccell.2020.08.020
# STAR★METHODS

## KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deposited Data</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TCGA RNA-seq BAM files</td>
<td>Genomic Data Commons</td>
<td><a href="https://portal.gdc.cancer.gov/legacy-archive/search/f">https://portal.gdc.cancer.gov/legacy-archive/search/f</a></td>
</tr>
<tr>
<td>TCGA somatic copy number alteration thresholded data</td>
<td>Genomic Data Commons</td>
<td><a href="https://gdc.cancer.gov/about-data/publications/pancanatlas">https://gdc.cancer.gov/about-data/publications/pancanatlas</a></td>
</tr>
<tr>
<td>TCGA somatic mutation data</td>
<td>Genomic Data Commons</td>
<td><a href="https://gdc.cancer.gov/about-data/publications/pancanatlas">https://gdc.cancer.gov/about-data/publications/pancanatlas</a></td>
</tr>
<tr>
<td>TCGA gene expression data</td>
<td>Genomic Data Commons</td>
<td><a href="https://gdc.cancer.gov/about-data/publications/pancanatlas">https://gdc.cancer.gov/about-data/publications/pancanatlas</a></td>
</tr>
<tr>
<td>TCGA patient clinic data</td>
<td>Genomic Data Commons</td>
<td><a href="https://gdc.cancer.gov/about-data/publications/pancanatlas">https://gdc.cancer.gov/about-data/publications/pancanatlas</a></td>
</tr>
<tr>
<td>Super-enhancer annotation of 86 tissues</td>
<td>(Hnisz et al., 2013)</td>
<td><a href="https://www.cell.com/cms/10.1016/j.cell.2013.09.053/attachment/c44ace85-27a5-4f4f-b7e4-db375a7f6f83/mmc7.zip">https://www.cell.com/cms/10.1016/j.cell.2013.09.053/attachment/c44ace85-27a5-4f4f-b7e4-db375a7f6f83/mmc7.zip</a></td>
</tr>
<tr>
<td>FANTOM cell line CAGE-seq data</td>
<td>(Andersson et al., 2014)</td>
<td><a href="http://fantom.gsc.riken.jp/5/datafiles/latest/basic/human.cell_line.hCAGE/">http://fantom.gsc.riken.jp/5/datafiles/latest/basic/human.cell_line.hCAGE/</a></td>
</tr>
<tr>
<td>FANTOM primary cell CAGE-seq data</td>
<td>(Andersson et al., 2014)</td>
<td><a href="http://fantom.gsc.riken.jp/5/datafiles/latest/basic/human.primary_cell.hCAGE/">http://fantom.gsc.riken.jp/5/datafiles/latest/basic/human.primary_cell.hCAGE/</a></td>
</tr>
<tr>
<td>FANTOM enhancer annotation</td>
<td>(Andersson et al., 2014)</td>
<td><a href="http://fantom.gsc.riken.jp/5/datafiles/latest/extra/Enhancers/human_permissive_enhancers_phase_1_and_2.bed">http://fantom.gsc.riken.jp/5/datafiles/latest/extra/Enhancers/human_permissive_enhancers_phase_1_and_2.bed</a></td>
</tr>
<tr>
<td>GETx RNA-seq and genotype data</td>
<td>dbGAP</td>
<td>dbGaP Accession phs000424.v8.p2</td>
</tr>
<tr>
<td>Chromatin interaction (Hi-C) data</td>
<td>The 3D Genome Browser</td>
<td><a href="http://promoter.bx.psu.edu/hi-c/publications.html">http://promoter.bx.psu.edu/hi-c/publications.html</a></td>
</tr>
</tbody>
</table>

## RESOURCE AVAILABILITY

### Lead Contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Han Liang (hliang1@mdanderson.org).

### Materials Availability

This study did not generate new unique reagents.

### Data and Code Availability

To facilitate the utilization of the results generated in this study by a broad community, we have provided all the information on our super-enhancer analysis in The Cancer eRNA Atlas (TCeA) data portal that can be accessed at https://bioinformatics.mdanderson.org/public-software/tcea. The supplemental datasets include 5 files. Briefly, Table S1 provides the detailed annotation of mappable non-coding super-enhancer regions (~377 Mb) surveyed in this study. Table S2 provides the details of the core super-enhancer regions (~5 Mb). Table S3 provides the information of >300,000 eRNA loci detected in >10,000 TCGA tumor samples. Table S4 provides the eRNA loci and genes associated with responses to immunotherapy. Table S5 provides the sample information used in this study.
METHOD DETAILS

Annotation of Super-enhancers
We obtained the annotation of super-enhancers in a panel of 86 human tissues and cell types from a previous study (Hnisz et al., 2013). In total, a list of 58,283 genomic regions was identified as super-enhancers in at least one tissue or cell type. This annotation was based on UCSC Hg19. We obtained all the exons under the attribute "ensembl_exon_id" from the GRCh37 ENSEMBL archive (https://grch37.ensembl.org/index.html) using the R package "biomaRt" (Durinck et al., 2009) and removed these exons and their flanking 100 bp sequences from the above-mentioned super-enhancer regions to avoid contamination of transcriptional signals with known genes. We then obtained a human genome benchmark (Zook et al., 2014) from ftp://ftp-trace.ncbi.nih.gov/shotgun/ftp/data/NA12878/analysis/NIST_union_callsets_06172013/union13callableMQonlymerged_addncert_nouncert_excludesimplerep_excludesegdups_excludedecoy_excludeRepSeqSTRs_noCNVs_v2.18_2mindatasets_5minYesNoRatio.bed.gz, that excluded the genomic regions that were ambiguous for mutation calling or short read mapping. Only the non-coding super-enhancer regions within the genome benchmark regions were considered for further eRNA expression analysis in this study to control for mappability. Following these steps, we generated a list of 65,728 genomic regions of super-enhancers (some of the original 58,283 super-enhancers were divided into multiple regions) for our eRNA expression analysis (Table S1). To identify a set of core super-enhancer regions with activities in multiple tissues and cell types, we divided the above sequences into non-overlapping 10 bp windows and compared all these windows with the original super-enhancer annotations in the 86 tissue and cell types to obtain their tissue specificity information. We obtained 1,531 genomic regions with super-enhancer activities in >20 of the 86 tissue and cell types (Table S2).

Analysis of eRNA and ChIP-seq H3K27ac Signals
For the H3K27ac data, we obtained two datasets from ENCODE (n = 50, most of which are normal human tissues and primary cells) (ENCODE Consortium, 2012) and the Cistrome database (n = 90, all of which are cancer cell lines) (Mei et al., 2017). The corresponding RNA-seq data for these samples were obtained from the ENCODE (n = 50) and CCLE (n = 90) database (Barretina et al., 2012), respectively. The identifiers of these samples in the corresponding database are provided in Table S5. Notably, the Cistrome database provides mapped bigwig files in the genome version of UCSC Hg38, and we converted the 1,531 super-enhancer regions from Hg19 to Hg38 using UCSCliftOver (Casper et al., 2018). For the ENCODE ChIP-seq samples, the level of H3K27ac on each super-enhancer was defined as the average fold change over the control as provided in the ENCODE bigwig file (Table S5). We used the average signal in the super-enhancer regions from the ENCODE RNA-seq bigwig files as the readout of eRNA expression. For the Cistrome H3K27ac dataset, we called the signal on each super-enhancer and then normalized it using the average signal across the whole genome to measure its H3K27ac level in a given sample. The corresponding RNA-seq bam files of the 90 cancer cell lines were obtained from CCLE (the bam file ids are provided in Table S5) (Barretina et al., 2012). The RPM of each of the 1,531 regions was calculated as the intensity of its eRNA expression. Since the ENCODE dataset and the Cistrome dataset are very different in terms of genomic coordinates, signal determination, normalization methods, and tissues of origin, we did not combine the two datasets and calculated the Spearman’s Rsos separately to measure the correlation between an eRNA and its local H3K27ac level for each super-enhancer in either dataset (Figures S1A and S1B). To evaluate the breadth of the positive correlations, we used a one-sided t-test on the Spearman’s Rsos to calculate p values (so that a large negative Rho would not pass the t-test). For each super-enhancer, the p values generated from the two datasets were combined into one using the Fisher’s method (Fisher, 1928) before being subjected to a q-value computation (Figure S1C) (Storey and Tibshirani, 2003). We then estimated the pi0, or the percentage of true null H0 (no positive correlation between the eRNA and H3K27ac) based on the distribution of the resulting combined p-values of the 1,531 super-enhancers using the R package “qvalue” (Figure S1D) (Storey and Tibshirani, 2003), Phison’s LFDR (Phipson, 2013), and Nettleton’s method (Nettleton et al., 2006).

Super-enhancer eRNA Expression Profiles
For tissue/cancer type (or subtype) level expression profiling, we first combined the 10,004 (including 720 normal samples and 9,284 tumors; see sample information in Table S5) TCGA bam files into merged bam files of 32 cancer types or the 66 cancer subtypes (Cancer Genome Atlas Research Network et al., 2013). For each of the 10 bp windows on the 1,531 super-enhancer regions, we calculated the RPKM and classified a window as “expressed” in a given cancer type if at least one read with mapping quality >20 was observed in ≥5 samples and >5% of the total samples of that cancer type. The 672 bp long genomic region of chr3:50,265,725-50,266,396 (Hg19) was selected for illustration in Figure 2A since (i) it was identified as a super-enhancer in nearly 5 samples and >5% of the total samples of that cancer type. The 672 bp long genomic region ofchr3:50,265,725-50,266,396 (Hg19) was selected for illustration in Figure 2A since (i) it was identified as a super-enhancer in nearly half (39/66) of the tissue/cell types, and (ii) nearly all of the positions in this region were expressed in >30 cancer types.

To identify eRNA peaks in the core super-enhancer regions, we searched the 1,531 regions, using a window size of 200 bp and a step length of 10 bp, for the local maximum RPKMs in each of the 32 cancer types. Two positions of local maximum RPKMs (in different cancer types) were merged if they were <20 bp away from each other. To merge two peaks, the peak with a local maximum value in more cancer types determined the position of the merged peak. If the two positions had the same number of supporting cancer types, the one with a higher RPKM value determined the position of the merged peak. A position identified as the local maximum RPKMs in ≥3 of the 32 cancer types was considered as a transcriptional peak on the core super-enhancer. To develop this cutoff, we removed the reads mapped to the top 10% positions with the highest RPKM in the 5 Mb core super-enhancers (to avoid the bias introduced by positions with extremely high expression levels) and randomly assigned new positions to the other reads. The
permuted reads were used as input for peak identification in the same way as described above. We used the 5% quantile of the RPKM of the resultant peaks as a cutoff. Peaks from real data with a lower RPKM value than the cutoff were defined as false identification. The FDR of peaks recurrent in a given number of cancer types were thus calculated. More than 98% of the peaks recurrent in $\geq 3$ of the 32 cancer types showed higher RPKM than the peaks identified using permuted reads (Figure S3A). The 200 bp window size was changed to 400 bp or 600 bp in Figure 3 to assess any potential technical bias. Using this strategy, we generated a list of 29,828 transcriptional peaks in the ~5 Mb region of the 1,531 core super-enhancers (related to Figures 2, 3, and S3). To identify eRNA expression peaks in the general super-enhancer regions ($n = 65,728; \sim 377$ Mb, see details in Table S1), we computed the RPKM values of all the non-redundant 10 bp windows. The sequence range for local maximum RPKM search was set to 140 bp as it is the length of a typical nucleosome. A total of 4,355,962 loci were identified as local maximum RPKMs of the (140 bp sequence) in at least one cancer type. For each locus, we calculated (i) the PC3 using the nucleosome positioning around it as described below and (ii) the relative peak height, which was computed as the local maximum RPKM minus the RPKM at its $\pm 50$ bp loci, whichever was smaller (Figure 3C). If an identified locus had the local maximum RPKM in more than one cancer type, we used the second largest relative peak height of these cancer types for this locus to avoid potential outlier effects. Among the ~4 million loci of local maximum RPKMs, we selected 302,951 loci with PC3 $<0$ and the relative peak height of $>0.05$ (in RPKM) as the final super-enhancer eRNA peaks. Notably, two peaks $<20$ bp away from each other (in different cancer types) were merged as described above. In total, we identified 302,951 loci (Table S3). To estimate the FDR of eRNA location identification with the cutoff of PC3$<0$ and the peak height $>0.05$ (in RPKM), we used a similar strategy as that for the 5 Mb core super-enhancer regions. Specifically, we removed the top 10% positions with the highest RPKM values and randomly assigned new positions to the other reads. The permuted reads were used as input for local maximum RPKM identification. The PC3 and the peak height of the resulted positions of local maximum RPKMs were calculated as that for the real data. We identified ~26,000 peaks passing the two criteria in three permutation analysis and estimated the eRNA location identification FDR to be $\sim 0.086$ (FDR $<0.1$). The peak on chromosome 22 was displayed using the R package “karyoplateR” (Gel and Serra, 2017). Chr22 was selected since it is the smallest chromosome and thus provides convenient visualization.

For sample-level expression profiling, the expression level for each of the 302,951 peaks was defined as the RPKM in its flanking 20 bp region. For all the 302,951 super-enhancer peaks, we computed their expression levels in 10,004 TCGA and 9,664 GTEx RNA-seq samples (GTEx Consortium, 2017), respectively. For the analysis of rRNA-depleted RNA-seq data, we obtained the data from GEO (GSE69360) (Choy et al., 2015). The raw reads were mapped to the reference genome hg19 using Tophat2.0 with default settings (Trapnell et al., 2012). The expression level of each eRNA was then defined in the same way as for the TCGA eRNA analysis.

**Motif Discovery and Chromatin Organization in Super-enhancer eRNA Peaks**

We used the FIMO software (Bailey et al., 2009) with default settings to identify all the DNA motifs annotated by the Mononucleotide human motifs database (Kulakovskiy et al., 2016) in the flanking 200 bp region of the 29,828 core super-enhancer peaks (related to Figures 3D and 3E). The FIMO outputs with FDR $<0.01$ were considered as valid motifs. We identified the splicing factor motifs by submitting the DNA sequences of interest to the S Bind online server with default settings (http://sfinmap.technion.ac.il/) (Paz et al., 2010).

For nucleosome analysis, we collected a panel of 29 MNase-seq profiles of various human tissues and cell types (including two sperm samples) (ENCODE Consortium, 2012; Descostes et al., 2014; Diermeier et al., 2014; Du et al., 2017; Gaffney et al., 2012; Gaidatzis et al., 2014; Gomez et al., 2016; Hammoud et al., 2009; Hu et al., 2011; Jiang et al., 2018; Jung et al., 2012; Kelly et al., 2012; Kfir et al., 2015; Lavender et al., 2016; Shah et al., 2014; West et al., 2014; Yazdi et al., 2015; Zhang et al., 2016). The raw reads for all these samples were downloaded from the SRA database (the SRR run IDs are provided in Table S5). Long reads were trimmed to 50 bp to make the samples more comparable in terms of mappability. All reads were mapped onto the human genome hg19 using Bowtie2 with default settings (Langmead and Salzberg, 2012). Only reads with mapping quality $>10$ were kept for further analysis. For a read mapped to the genomic locus of X, we extended the read and considered the region between X+40 to X+110 as being occupied by a nucleosome confidently (Zhang et al., 2008). The normalized read number (Z-score) on each genomic locus was considered as the readout of nucleosome occupancy (related to Figures 4 and S3). For evolutionary analysis, we converted the genomic locus on hg19 to mouse (UCSC genome version mm9) and pig (UCSC genome version susScr3) using the UCSC liftOver software (Jiang et al., 2018). For the PCA, we computed, across 27 tissues (the two samples were excluded), the mean nucleosome signal of all 10 bp windows within the flanking 140 bp region relative to each of the ~4 million loci of local maximum RPKM, generating a matrix of 29 x 4,355,962 as the input. The first three components, PC1, PC2, and PC3, explained 52.3%, 18.2%, and 13.3% of the total variation (summed up to be 83.9%), respectively, and were kept for further analysis (related to Figures 5 and S4). Although the PCA included all the 4 million peaks, only the first 10,000 are displayed in Figure 5A and S4A–S4C for convenient visualization. The GTEx eQTLs were obtained from the GTEx data portal (GTEx_Analysis_v7_eQTL.tar.gz) under the link https://gtexportal.org/home/datasets (GTEx Consortium, 2017). For each quantile in Figures 5E, 5F, and 5i, we defined the probability for a common SNP to be a GTEx eQTL as the number of GTEx eQTLs in the locus’s flanking 20 bp divided by the total number of common SNPs (minor allele frequency $>20\%$ in 1000 Genome Project dataset) in the same regions. For the analysis of CAGE-seq signal flanking the eRNA loci, we collected 266 CAGE-seq datasets (in ctss format) of human cell lines from http://fantom.gsc.riken.jp/5/datafiles/latest/basic/human.cell.line.hCAGE/, and 512 human primary cells from http://fantom.gsc.riken.jp/5/datafiles/latest/basic/human.primary.cell.hCAGE/ as listed in Table S5. Since the ctss files contained the 5-end of CAGE-seq reads from both FANTOM promoters and enhancers, we selected those from FANTOM eRNAs using reads mapped to the FANTOM enhancers.
Research Network et al., 2013). We considered SCNAs without overlaps with any genes (or ncRNA) annotated by the Human GEN

data available. This 3,919 450K array used in TCGA project. A total of 8,430 TCGA samples have both methylation and super-enhancer peak expression

these events is provided in our data portal.

found 3,678/1,047 non-coding amplification/deletion SCNAs involving at least one eRNA locus identified in this study. A full list of

to measure the association between its expression (determined as either group, RPKM, or log2RPKM) and clinical outcomes

to >10 samples and >10% of the total samples in that cancer type. For each loci, we used the Cox regression coefficient

10 bp windows in the aligned sequences (Figures S5A and S5B).

The relative CAGE-seq signal was then defined as the number of reads in a given window normalized by the average number of all

10 bp windows in the aligned sequences (Figures S5A and S5B).

For 15 (out of 29) non-sperm, paired-end MNase-seq profiles, we called individual nucleosomes using DANPOS2.0 (Chen et al.,

2013). The pair-end reads were mapped to the reference genome hg19 using Bowtie2 (Langmead and Salzberg, 2012) with default

settings. The bowtie results were then converted into bed files before being sorted, using the bamtool function in bedtools (Quinian

and Hall, 2010). The bed files were input to DANPOS2.0 using danpos.py with default settings. We defined an eRNA locus to overlap with

a nucleosome if the “center” parameter from the DANPOS2.0 result was within the ± 20 bp region of that eRNA locus (Figure S6G).

eRNA Expression Analysis for Tumor Response to Immunotherapy

We obtained the raw reads of 28 melanoma tumors receiving anti-PD1 immunotherapy from the SRA database (see the SRR IDs in

Table S5)(Hugo et al., 2017). The reads were mapped to the human genome (UCSC hg19) using Bowtie2 with default settings (Langmead and Salzberg, 2012). Only reads with mapping quality >20 were kept for further analysis. We found 37,651 super-enhancer eRNA loci identified in the TCGA melanoma cancer type (SKCM) with detectable expression in ≥ 14 (50%) of the 28 tumors. Each of these eRNAs was subjected to ANOVA test among the three groups with differential responses to the anti-PD1 immunotherapy. The p-values were converted to q-values to adjust for multiple comparisons. The 164 eRNA loci with q<0.05 are provided in Table S4 and displayed using the R package “karyoplateR” (Gel and Serra, 2017). The gene-level expressions of these 28 tumors were obtained from the original study. We found 36 GTeX eQTLs on the 164 eRNA loci associated with 36 genes (Table S4). There were no common SNPs/GTEx eQTLs within the other 128 eRNA loci, and thus, they were not included in the enrichment analysis. The 36 downstream genes of these eQTLs were subjected to GSEA using the GSEA online server (http://software.broadinstitute.org/gsea/index.jsp) with default settings (Subramanian et al., 2005). The TIDE scores of the 310 TCGA SKCM tumors for immunotherapy response prediction were obtained from http://tide.dfcI.harvard.edu/ (Jiang et al., 2018). For the cohort of 42 patients receiving anti-

CTLA-4 immunotherapy, raw reads were obtained from the SRA database (see the SRR IDs in Table S5) (Van Allen et al., 2015). The reads were mapped to the human genome (UCSC hg19) using Bowtie2 with default settings. Only reads with mapping quality >20 were kept for further analysis. The log₂RPKM of the 8 genes selected from GSEA were calculated and summed up as a combined score for CD8+ T cell functionality. To test whether this score was associated with better survival in the 42 patients, we used the R package “Fhtest” to perform a one-sided FH-test on its effect on the one-year survival rate (Oller and Langohr, 2017).

Integrative Analysis of eRNA Loci with Other TCGA Molecular and Clinical Data

For somatic copy-number analysis, we surveyed a list of 138,781 focal somatic copy-number alterations (SCNAs) identified with the

GISTIC software with an FDR <0.05 (Mermel et al., 2011) by the TCGA Pan-Cancer analysis consortium (Cancer Genome Atlas

Research Network et al., 2013). The pair-end reads were compared with the 302,951 eRNA loci identified in this study, and the relative
distances of each read to all of its nearby eRNA loci (<1 kb) were calculated. We counted reads within 1 kb distance of two (or more)
eRNA loci multiple times for all the eRNA loci. The 302,951 eRNA loci and their flanking 1 kb DNA were then aligned with the loci of the eRNA peak at the center. We then counted the number of reads mapped to all the 10 bp tandem windows within these aligned sequences. Windows with the same relative distance to all the eRNA loci were combined for the calculation of the CAGE-seq signal. The relative CAGE-seq signal was then defined as the number of reads in a given window normalized by the average number of all

10 bp windows in the aligned sequences (Figures S5A and S5B).

For 15 (out of 29) non-sperm, paired-end MNase-seq profiles, we called individual nucleosomes using DANPOS2.0 (Chen et al.,

2013). The pair-end reads were mapped to the reference genome hg19 using Bowtie2 (Langmead and Salzberg, 2012) with default

settings. The bowtie results were then converted into bed files before being sorted, using the bamtool function in bedtools (Quinian

and Hall, 2010). The bed files were input to DANPOS2.0 using danpos.py with default settings. We defined an eRNA locus to overlap with

a nucleosome if the “center” parameter from the DANPOS2.0 result was within the ± 20 bp region of that eRNA locus (Figure S6G).

eRNA Expression Analysis for Tumor Response to Immunotherapy

We obtained the raw reads of 28 melanoma tumors receiving anti-PD1 immunotherapy from the SRA database (see the SRR IDs in

Table S5)(Hugo et al., 2017). The reads were mapped to the human genome (UCSC hg19) using Bowtie2 with default settings (Langmead and Salzberg, 2012). Only reads with mapping quality >20 were kept for further analysis. We found 37,651 super-enhancer eRNA loci identified in the TCGA melanoma cancer type (SKCM) with detectable expression in ≥ 14 (50%) of the 28 tumors. Each of these eRNAs was subjected to ANOVA test among the three groups with differential responses to the anti-PD1 immunotherapy. The p-values were converted to q-values to adjust for multiple comparisons. The 164 eRNA loci with q<0.05 are provided in Table S4 and displayed using the R package “karyoplateR” (Gel and Serra, 2017). The gene-level expressions of these 28 tumors were obtained from the original study. We found 36 GTeX eQTLs on the 164 eRNA loci associated with 36 genes (Table S4). There were no common SNPs/GTEx eQTLs within the other 128 eRNA loci, and thus, they were not included in the enrichment analysis. The 36 downstream genes of these eQTLs were subjected to GSEA using the GSEA online server (http://software.broadinstitute.org/gsea/index.jsp) with default settings (Subramanian et al., 2005). The TIDE scores of the 310 TCGA SKCM tumors for immunotherapy response prediction were obtained from http://tide.dfcI.harvard.edu/ (Jiang et al., 2018). For the cohort of 42 patients receiving anti-

CTLA-4 immunotherapy, raw reads were obtained from the SRA database (see the SRR IDs in Table S5) (Van Allen et al., 2015). The reads were mapped to the human genome (UCSC hg19) using Bowtie2 with default settings. Only reads with mapping quality >20 were kept for further analysis. The log₂RPKM of the 8 genes selected from GSEA were calculated and summed up as a combined score for CD8+ T cell functionality. To test whether this score was associated with better survival in the 42 patients, we used the R package “Fhtest” to perform a one-sided FH-test on its effect on the one-year survival rate (Oller and Langohr, 2017).

Integrative Analysis of eRNA Loci with Other TCGA Molecular and Clinical Data

For somatic copy-number analysis, we surveyed a list of 138,781 focal somatic copy-number alterations (SCNAs) identified with the

GISTIC software with an FDR <0.05 (Mermel et al., 2011) by the TCGA Pan-Cancer analysis consortium (Cancer Genome Atlas

Research Network et al., 2013). We considered SCNAs without overlaps with any genes (or ncRNA) annotated by the Human GEN-

CODE database v18 (https://www.gencodegenes.org/human/releases.html) as non-coding driver events (Frankish et al., 2018). We found 3,678/1,047 non-coding amplification/deletion SCNAs involving at least one eRNA locus identified in this study. A full list of these events is provided in our data portal.

For CpG DNA methylation analysis, we selected 3,919 eRNA loci containing at least one CpG probe in the Human Methylation

450K array used in TCGA project. A total of 8,430 TCGA samples have both methylation and super-enhancer peak expression data available. This 3,919×8,430 matrix is provided in our data portal. For differential CpG methylation analysis, we considered the 10 cancer types with >10 tumor-normal paired samples and used paired t-test to determine the significance of the methylation changes (ranging from 0% to 100%) between the normal and tumor samples. A CpG methylation change with an FDR <0.01 and an absolute change >20% was considered as a significant hit.

For prognostic analysis, we surveyed only (i) the eRNA loci annotated in a given cancer type (Table S3), and (ii) with detectable

expression in >10 samples and >10% of the total samples in that cancer type. For each loci, we used the Cox regression coefficient

to measure the association between its expression (determined as either group, RPKM, or log₂RPKM) and clinical outcomes

(measured as either overall survival [OS], disease-specific survival [DSS], or progression-free interval [PFI]) (Liu et al., 2018). The expression level “group” was a binary parameter generated by dividing the patients into two groups according to the RPKM of the peak of interest, with the lower half (RPKM ≤ median) assigned as 0 and the higher half (RPKM >median) assigned as 1. The resulting p-values were converted into q-values to correct for multiple comparisons (Storey and Tibshirani, 2003). A list of 49,849 eRNA loci associated with any of the clinical outcomes (q <0.05) is provided in our data portal.

Analysis of eRNA-Locus/Gene Co-expression and 3D Chromatin Interactions

We calculated the co-expression patterns between each eRNA-gene pair across the 32 cancer types and selected those that were

consistently co-expressed/reversed in at least 3 cancer types. In each cancer type, we required a p-value with Bonferroni correction
to be <0.01 and an absolute Spearman’s Rho to be >0.3. We observed ~161 million eRNA-gene pairs meeting these criteria, among which 72.1% were positively co-expressed. We applied the same cutoffs to the protein-coding genes across the 32 cancer types to identify ~63 million gene-gene interactions, of which about half (55%) were positive correlations. From 3D Genome Browser (Wang et al., 2018), we then obtained the HiC chromatin loops calculated by Peakachu (https://github.com/tariks/peakachu) from 56 HiC datasets. We compared the HiC loops with the co-expressed eRNA-gene pairs and selected 32,298 pairs connected by at least one loop in any of the 56 HiC profiles, of which 96.6% were positively co-expressed (Figures S7D–S7H).